Published in BMJ Open Gastroenterol on April 04, 2017
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008) 11.44
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Reversal of hepatic fibrosis -- fact or fantasy? Hepatology (2006) 2.81
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One (2013) 1.89
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol (2015) 1.58
Treating hepatitis C in lower-income countries. N Engl J Med (2014) 1.52
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol (2014) 1.36
The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med (2014) 1.33
Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol (2014) 1.16
Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat (2015) 1.11
Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS (2015) 1.11
Health economic assessment: cost-effectiveness thresholds and other decision criteria. Int J Environ Res Public Health (2010) 1.03
Treatment of patients with hepatitis C and cirrhosis. Hepatology (2002) 1.02
[Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2013) 1.02
Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinics. HIV Med (2012) 0.96
[Epidemiology of chronic hepatitis C in Germany--an analysis of 10,326 patients in hepatitis centres and outpatient units]. Z Gastroenterol (2008) 0.93
Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol (2015) 0.91
Reading a cost-effectiveness or decision analysis study: Five things to consider. Neurol Clin Pract (2013) 0.90
Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort. Z Gastroenterol (2015) 0.87
Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. Eur J Gastroenterol Hepatol (2014) 0.82
Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. Health Aff (Millwood) (2015) 0.81
Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care (2016) 0.81
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach. BMC Infect Dis (2015) 0.79
Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat (2015) 0.78
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. Drugs R D (2015) 0.75
First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany. Eur J Clin Pharmacol (2015) 0.75